Incyte Corp Analyst and Investor Event Transcript - Thomson StreetEvents

Incyte Corp Analyst and Investor Event Transcript

Incyte Corp Analyst and Investor Event Transcript - Thomson StreetEvents
Incyte Corp Analyst and Investor Event Transcript
Published Dec 12, 2022
18 pages (14295 words) — Published Dec 12, 2022
Price US$ 54.00  |  Buy this Report Now

About This Report

  
Abstract:

Edited Transcript of INCY.OQ corporate analyst meeting

  
Brief Excerpt:

...All right. Good evening, everybody. Thank you for joining us. We'll start the meeting. It's really good to be here at the American Society of Hematology in person, in New Orleans, and this meeting is also joined by people on Webex as well. So thank you for being here. I just want to tell everybody from the beginning that safe harbor rules govern my remarks, those of my colleagues on the stage with me tonight and as well as any forward-looking statements, and I'd tell you to consult our SEC documents and for risks associated with anything we speak about. In terms of tonight's agenda, I am Steven Stein. I'm the Incyte Chief Medical Officer and Head of Development, and I'll be taking you through the agenda tonight and then at the end, wrapping up and -- as well as the Q&A, for which we should have about 15 to 20 minutes if everything goes according to plan. The presence we have at ASH is a really big deal for Incyte this year, both quantitatively and qualitatively. We had 57 abstracts accepted,...

  
Report Type:

Transcript

Source:
Thomson StreetEvents
Company:
Incyte Corp
Ticker
INCY.OQ
Time
2:00am GMT
Format:
PDF Adobe Acrobat
Buy Now

The following is excerpted from the question-and-answer section of the transcript.

(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)

Question: Jessica Macomber Fye - JPMorgan Chase & Co, Research Division - Analyst : Great. Jess Fye, JPMorgan. For parsaclisib, what's the threshold for spleen reduction in the primary endpoint in the LIMBER-304 [pro responder] trial? Just trying to think about what we can learn from the Phase II data as it relates to that pivotal trial? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. DECEMBER 12, 2022 / 2:00AM, INCY.OQ - Incyte Corp Analyst and Investor Event

Question: Jessica Macomber Fye - JPMorgan Chase & Co, Research Division - Analyst : Okay. And for 928 ALK2, I know you said we'll get an update next year. Do you expect to have found a go-forward dose by the end of next year? Unidentified Company Representative Peter, do you want to answer that? Peter Langmuir Yes. So I think we'll see, I mean the dose escalation is continuing. And then obviously, it sort of depends whether we hit tolerability issues, whether we can continue to escalate to improve efficacy. But I think our hope is to have a dose and a decision on moving forward by the end of the year.

Table Of Contents

Incyte Corp at Guggenheim Healthcare Talks Oncology Day Transcript – 2023-02-08 – US$ 54.00 – Edited Transcript of INCY.OQ presentation 8-Feb-23 6:35pm GMT

Incyte Corp Q4 2022 Earnings Call Summary – 2023-02-07 – US$ 54.00 – Edited Brief of INCY.OQ earnings conference call or presentation 7-Feb-23 1:00pm GMT

Incyte Corp Q4 2022 Earnings Call Transcript – 2023-02-07 – US$ 54.00 – Edited Transcript of INCY.OQ earnings conference call or presentation 7-Feb-23 1:00pm GMT

Incyte Corp at JPMorgan Healthcare Conference Transcript – 2023-01-09 – US$ 54.00 – Edited Transcript of INCY.OQ presentation 9-Jan-23 3:30pm GMT

Incyte Corp at Goldman Sachs CEOs Unscripted Conference Transcript – 2023-01-05 – US$ 54.00 – Edited Transcript of INCY.OQ presentation 5-Jan-23 2:45pm GMT

Incyte Corp at Bank of America Biotech SMID Cap Conference Transcript – 2022-12-07 – US$ 54.00 – Edited Transcript of INCY.OQ presentation 7-Dec-22 1:35pm GMT

Incyte Corp at Evercore ISI HealthCONx Conference (Virtual) Transcript – 2022-11-29 – US$ 54.00 – Edited Transcript of INCY.OQ presentation 29-Nov-22 5:35pm GMT

Incyte Corp Q3 2022 Earnings Call Summary – 2022-11-01 – US$ 54.00 – Edited Brief of INCY.OQ earnings conference call or presentation 1-Nov-22 12:00pm GMT

Incyte Corp Q3 2022 Earnings Call Transcript – 2022-11-01 – US$ 54.00 – Edited Transcript of INCY.OQ earnings conference call or presentation 1-Nov-22 12:00pm GMT

Incyte Corp at Morgan Stanley Global Healthcare Conference Transcript – 2022-09-12 – US$ 54.00 – Edited Transcript of INCY.OQ presentation 12-Sep-22 4:30pm GMT

More from Thomson StreetEvents

Thomson StreetEvents—Thomson StreetEvents is a leading provider of Web-based solutions for the investment community, offering services that transform the way companies communicate and meet disclosure requirements while assisting investors in managing and leveraging this information. Thomson StreetEvents service offers institutional investors a one-stop solution for managing corporate disclosure information by aggregating conference calls, webcasts, transcripts, call summaries, and other financial information into a time-saving, efficiency tool.
Purchase Thomson StreetEvents' Transcripts (verbatim reports) and Briefs (call summaries) of earnings, guidance, M&A and other corporate calls directly through Alacra. Discounted prices apply to reports produced over two weeks ago.

About the Author


Cite this Report

  
MLA:
Thomson StreetEvents. "Incyte Corp Analyst and Investor Event Transcript" Dec 12, 2022. Alacra Store. May 15, 2025. <http://www.alacrastore.com/thomson-streetevents-transcripts/Incyte-Corp-Analyst-and-Investor-Event-T15382954>
  
APA:
Thomson StreetEvents. (2022). Incyte Corp Analyst and Investor Event Transcript Dec 12, 2022. New York, NY: Alacra Store. Retrieved May 15, 2025 from <http://www.alacrastore.com/thomson-streetevents-transcripts/Incyte-Corp-Analyst-and-Investor-Event-T15382954>
  
US$ 54.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Credit Research from one place.